safusidenib (AB-218) / Daiichi Sankyo, Baoyuan Biopharma 
Welcome,         Profile    Billing    Logout  
 0 Diseases   2 Trials   2 Trials   15 News 
  • ||||||||||  safusidenib (AB-218) / Daiichi Sankyo, Baoyuan Biopharma
    Enrollment open, Trial completion date, Trial primary completion date:  Safusidenib Phase 2 Study in IDH1 Mutant Glioma (clinicaltrials.gov) -  May 24, 2023   
    P2,  N=95, Recruiting, 
    Trial primary completion date: Sep 2023 --> Mar 2023 Not yet recruiting --> Recruiting | Trial completion date: Feb 2027 --> Jul 2027 | Trial primary completion date: Jan 2026 --> Mar 2027
  • ||||||||||  safusidenib (AB-218) / Daiichi Sankyo, Baoyuan Biopharma
    Trial completion date, Trial primary completion date:  Study of DS-1001b in Patients With Gene IDH1-Mutated Gliomas (clinicaltrials.gov) -  Mar 15, 2021   
    P=N/A,  N=47, Active, not recruiting, 
    These results are expected to provide a new therapeutic approach for a subset of patients who have difficulty responding to mutant IDH1 inhibitors. Trial completion date: Mar 2022 --> Mar 2026 | Trial primary completion date: Jan 2022 --> Jan 2021
  • ||||||||||  Journal, PARP Biomarker, IO Biomarker:  Novel IDH1-Targeted Glioma Therapies. (Pubmed Central) -  Sep 21, 2020   
    Both agents are still in early clinical phases for glioma therapy, as are a number of additional candidates (including AG-881, BAY1436032, and DS1001)...An alternative approach to target the IDH1 mutation is by the induction of synthetic lethality with compounds that target poly (ADP-ribose) polymerase (PARP), glutamine metabolism, and the Bcl-2 family of proteins. We conclude that within the last decade, several approaches have been devised to therapeutically target the IDH1 mutation, and that, potentially, both IDH1 inhibitors and synthetic lethal approaches might be relevant for future therapies.
  • ||||||||||  safusidenib (AB-218) / Daiichi Sankyo, Baoyuan Biopharma
    Enrollment open:  A Study of DS-1001b in Patients With Chemotherapy- and Radiotherapy-Naive IDH1 Mutated WHO Grade II Glioma (clinicaltrials.gov) -  Aug 7, 2020   
    P2,  N=25, Recruiting, 
    We conclude that within the last decade, several approaches have been devised to therapeutically target the IDH1 mutation, and that, potentially, both IDH1 inhibitors and synthetic lethal approaches might be relevant for future therapies. Not yet recruiting --> Recruiting
  • ||||||||||  safusidenib (AB-218) / Daiichi Sankyo, Baoyuan Biopharma
    Trial completion date, Trial primary completion date:  Study of DS-1001b in Patients With Gene IDH1-Mutated Gliomas (clinicaltrials.gov) -  Feb 28, 2020   
    P=N/A,  N=60, Active, not recruiting, 
    The present data strongly suggest that inhibition of mutant IDH1 is a promising therapeutic approach in chondrosarcoma, particularly for the treatment of relapsed or dedifferentiated chondrosarcoma. Trial completion date: Mar 2020 --> Mar 2022 | Trial primary completion date: Jan 2020 --> Jan 2022
  • ||||||||||  safusidenib (AB-218) / Daiichi Sankyo, Baoyuan Biopharma
    Enrollment closed:  Study of DS-1001b in Patients With Gene IDH1-Mutated Gliomas (clinicaltrials.gov) -  Apr 10, 2019   
    P=N/A,  N=60, Active, not recruiting, 
    Legal entity responsible for the study: Daiichi Sankyo Co., Ltd. Recruiting --> Active, not recruiting
  • ||||||||||  safusidenib (AB-218) / Daiichi Sankyo, Baoyuan Biopharma
    Enrollment open:  Study of DS-1001b in Patients With Gene IDH1-Mutated Gliomas (clinicaltrials.gov) -  Feb 23, 2017   
    P=N/A,  N=60, Recruiting, 
    Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting